Régis Villet, Exec. Mba, Phd, Hdr Email & Phone Number

Lyon, Fr

Lyon, Fr

As a Business Developer and Alliance Manager at BIOASTER, I leverage my dual background in science and business to forge strategic alliances, manage key portfolios, and stimulate innovation in microbiology. I am committed to adding value to our partners, clients, and BIOASTER while promoting the forefront of the digital revolution, including Artificial Intelligence solutions.Key Responsibilities:- Identification and management of new strategic partnerships- Creation of synergies and establishment of strategic collaborations- Management of key portfolios- Development of collaborative projects tailored to our clients' specific needs- Business development plan strategy- Contract negotiation - Adding value to our clients and partners through innovative project implementation- Development of international collaborations- Maintaining strong relationships with our clients- Utilizing AI and the digital solutions to enhance BIOASTER's activitiesI adopt a client-centered approach, aiming to provide competitive advantages through innovative solutions that meet our partners' strategic needs. My goal is to accelerate research, overcome technological hurdles, and enable the rapid market launch of solutions beneficial for patients.

Lyon, Fr

In this position, I develop and manage the activity of the Microbiology Unit (up to 15 collaborators) and contribute to the scientific strategy & development of the Institute in conjunction with the Programs (Antimicrobials, Vaccines, Microbiota and Diagnostic). Both internally and externally, I create the conditions for technological innovation and scientific emulation in the field of infectious diseases by creating effective synergies. Among partners, both academic and industrial, I promote the integration of know-how and technological offer into the institute's collaborative projects, in response to the partners needs.

Paris, 13, Fr

Team lead related to biofilm-related clinical and industrial research programs♦ 1 patent : biofilmCare FR1659459 - PCT/FR2017052646Method and device for preparing and washing biofilms for analysis. This non-aggressive and non-destructive washing technique preserves the integrity of the biofilms. It allows the in-depth study of newly formed (native) or mature biofilms, by qualifying and quantifying the living bacteria making up the biofilm. It constitutes the ideal basis for an analysis of biofilms in various fields, from health to the food industry, whether of bacterial, fungal or algal origin.2 peer reviewed publications :♦ “A steam-based method to investigate biofilm“, Tasse J, Cara A, Saglio, M, Villet R & Laurent F. Sci. Rep. 2018♦ “Processing and antibacterial properties of chitosan-coated alginate fibers“, Dumont M, VilletR, Guirand M, Montembault A, Delair T, Lack S, Barikosky M, Vrepet A, Alcouffe P, Laurent F, David L. Carbohydrate Polymers 2018

Boston, Massachusetts, Us

Research and team lead related to the identification of antimicrobial resistance mechanisms in Staphylococcus aureus7 peer reviewed publications :♦ “Functions of a GyrBA Fusion and the Interaction with QnrB and Quinolones”, Chen C, Villet R, Jacoby GA, Hooper DC. AAC. 2015♦ “Genes contributing to Staphylococcus aureus success in abscess and infection related ecologies”, Valentino M, Foulston L, Sadaka S, Kos V,Villet R, Santa Maria Jr. J, Lazinski D, Camilli A, Walker S, Hooper D and Gilmore M. MBio. 2014♦ “Regulation of Expression of abcA and Its Response to Environmental Conditions”, Villet R, Truong-Bolduc QC, Wang Y, Estabrooks Z and Hooper D. J Bacteriol. 2014♦ “Role of Tet38 Efflux Pump in S. aureus Survival and Resistance to Fatty acids”, Truong-Bolduc QC, Villet R, Estabrooks Z, Routray A, Maira-Litran T, Onodera Y and Hooper D. J Infect Dis 2014♦ “Moenomycin Resistance Mutations in Staphylococcus aureus Reduce Peptidoglycan Chain Length and Cause Aberrant Cell Division”, Rebets Y, Lupoli T, Qiao Y, Schirner K, Villet R, Hooper D, Kahne D, Walker S. ACS Chem Biol 2014♦ "Cochlin produced by follicular dendritic cells promotes anti-bacterial innate immunity" Py B, Gonzalez S, Long K, Kim Y, Yao J, Zhu H, Degauque N, Villet R, PatrickYL, Kim MS, Gadjeva M, Pier G, Carroll M, Yuan J. Immunity 2013♦ “Reduced Aeration Affects the Expression of the NorB Efflux Pump of Staphylococcus aureus by Posttranslational Modification of MgrA” Truong-Bolduc QC, Hsing LC, Villet R, Bolduc GR, Estabrooks Z, Taguezem GF and Hooper DC. J Bacteriol. 2012

Genève, Ch

Research lead related to the identification of antimicrobial resistance mechanisms in Staphylococcus aureus1 peer reviewed publication :♦ “Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance” Didier JP, Villet R, Huggler E, Lew DP, Hooper DC, Kelley WL, Vaudaux P. Antimicrob Agents Chemother. 2011

Executive Master Of Business Administration (Emba), Corporate Executive

Hdr (Habilitation To Supervise Research), Antimicrobial Resistance (Amr)

Certificate, English As A Second Language

Ph.D, Biochemistry, Molecular Biology

Master Of Science (Msc), Pharmacochemistry, Biochemical Pharmacology And Drug Metabolism